Kymera Therapeutics, Inc. (KYMR)
116.90
-0.38
(-0.32%)
USD |
NASDAQ |
Sep 04, 10:04
Kymera Therapeutics Cash from Investing (Quarterly) : 20.04M for June 30, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 20.04M |
| March 31, 2026 | -142.84M |
| December 31, 2025 | -394.40M |
| September 30, 2025 | -235.30M |
| June 30, 2025 | 60.02M |
| March 31, 2025 | 48.62M |
| December 31, 2024 | 68.57M |
| September 30, 2024 | -157.68M |
| June 30, 2024 | 15.64M |
| March 31, 2024 | -330.61M |
| December 31, 2023 | 18.95M |
| September 30, 2023 | 60.51M |
| June 30, 2023 | 35.84M |
| March 31, 2023 | 24.58M |
| Date | Value |
|---|---|
| December 31, 2022 | -49.67M |
| September 30, 2022 | -37.48M |
| June 30, 2022 | 81.80M |
| March 31, 2022 | 25.86M |
| December 31, 2021 | -68.02M |
| September 30, 2021 | -136.86M |
| June 30, 2021 | 60.72M |
| March 31, 2021 | 44.32M |
| December 31, 2020 | -3.99M |
| September 30, 2020 | -334.32M |
| June 30, 2020 | -46.87M |
| March 31, 2020 | -37.40M |
| December 31, 2019 | 61.96M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 43.68M |
| Oncolytics Biotech, Inc. | 0.00 |
| Sangamo Therapeutics, Inc. | -0.013M |
| Sarepta Therapeutics, Inc. | -93.37M |
| Anixa Biosciences, Inc. | 0.422M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -54.06M |
| Cash from Financing (Quarterly) | 14.42M |
| Free Cash Flow | -237.96M |
| Free Cash Flow Per Share (Quarterly) | -0.5555 |
| Free Cash Flow to Equity (Quarterly) | -52.63M |
| Free Cash Flow to Firm (Quarterly) | -54.46M |
| Free Cash Flow Yield | -2.18% |